Epigenetics: A new pathway to tackle residual risk?
CME accredited symposium to be held at ESC 2019 in Paris, FranceAgenda - Aug. 31, 2019 - ESC Paris, France
If you are attending ESC 2019 in Paris, France, you are cordially invited to attend this CME accredited Symposium
Saturday, August 31, 2019: 15:30 – 16:30 hrs
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and CVD
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
- Introduction, Ulf Landmesser, MD, Berlin, Germany
- Challenges in targeting residual risk in diabetic patients, post ACS, Peter Libby, MD, Boston, USA
- BET inhibition, an epigenetic pathway: how could BET inhibition modulate atherothrombotic risk, Wouter Jukema, MD, Leiden, the Netherlands
- Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition?,Kausik Ray, MD, London, United Kingdom
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
This symposium is funded by an unrestricted educational grant received from Resverlogix